Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Cost-Benefit Analysis. Found 11 abstracts

Geynisman DM, Hu JC, Liu L, Tina Shih YC. Treatment patterns and costs for metastatic renal cell carcinoma patients with private insurance in the United States. Clin Genitourin Cancer. 2015 Apr;13(2):e93-100.
Nghiem VT, Davies KR, Beck JR, Follen M, MacAulay C, Guillaud M, Cantor SB. Economic evaluation of DNA ploidy analysis vs liquid-based cytology for cervical screening. Br J Cancer. 2015 Jun 09;112(12):1951-7.   PMCID: PMC4580387
Geynisman DM, Chien CR, Smieliauskas F, Shen C, Shih YC. Economic evaluation of therapeutic cancer vaccines and immunotherapy: a systematic review. Hum Vaccin Immunother. 2014 Jan;10(11):3415-24.   PMCID: PMC4514043
Martin JM, Handorf EA, Kutikov A, Uzzo RG, Bekelman JE, Horwitz EM, Smaldone MC. The rise and fall of prostate brachytherapy: use of brachytherapy for the treatment of localized prostate cancer in the National Cancer Data Base. Cancer. 2014 Jul 15;120(14):2114-21.   PMCID: 4429530
Shen C, Chien CR, Geynisman DM, Smieliauskas F, Shih YC. A review of economic impact of targeted oral anticancer medications. Expert Rev Pharmacoecon Outcomes Res. 2014 Feb;14(1):45-69.
Meropol NJ, Schrag D, Smith TJ, Mulvey TM, Langdon RM, Blum D, Ubel PA, Schnipper LE, American Society of Clinical O. American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol. 2009 Aug 10;27(23):3868-74.
Wong YN, Meropol NJ, Speier W, Sargent D, Goldberg RM, Beck JR. Cost implications of new treatments for advanced colorectal cancer. Cancer. 2009 May 15;115(10):2081-91.   PMCID: PMC2875773
Konski A, Watkins-Bruner D, Feigenberg S, Hanlon A, Kulkarni S, Beck JR, Horwitz EM, Pollack A. Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer. Int J Radiat Oncol Biol Phys. 2006 Aug;66(2):408-15.
Owen JB, Grigsby PW, Caldwell TM, Konski AA, Johnson DJ, Demas WF, Movsas B, Jones CU, Wasserman TH. Can costs be measured and predicted by modeling within a cooperative clinical trials group? Economic methodologic pilot studies of the radiation therapy oncology group (RTOG) studies 90-03 and 91-04. Int J Radiat Oncol Biol Phys. 2001 Mar;49(3):633-9.
Horwitz EM, Hanks GE. Three-dimensional conformal radiation therapy: what are the costs and benefits?. Surg Oncol Clin N Am. 2000 Jul;9(3):455-67, viii.
Horwitz EM, Hanlon AL, Pinover WH, Hanks GE. The cost effectiveness of 3D conformal radiation therapy compared with conventional techniques for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 1999 Dec;45(5):1219-25.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Cost-Benefit Analysis

economics Cost-Benefit Analysis Health Care Costs methods Male radiotherapy therapeutic use Aged Antineoplastic Agents United States Neoplasms Prostatic Neoplasms Conformal Radiotherapy drug therapy Markov Chains pathology Human Neoplasm Metastasis Medicare Comparative Study Monoclonal Antibodies Economic Models Drug Industry statistics & numerical data Cohort Studies Factual Databases Retrospective Studies Drug Costs Follow-Up Studies Female Health Insurance trends 80 and over Aged therapy Pilot Projects prostatectomy Income Brachytherapy Intensity-Modulated Radiotherapy Decision Support Techniques genetics Delivery of Health Care Patient Education as Topic Radiation Oncology Utilization Review Treatment Outcome Insurance Coverage Physician-Patient Relations Feasibility Studies Radiotherapy Dosage Brain Neoplasms Quality-Adjusted Life Years Randomized Controlled Trials US Gov't Support-PHS Oral Administration Radiotherapy Head and Neck Neoplasms Renal Cell Carcinoma Kidney Neoplasms Research Support as Topic prostatic neoplasms Colorectal Neoplasms Case-Control Studies brachytherapy Cancer Vaccines Cancer Care Facilities Insurance Claim Review Suburban Population Hospital Charges Androgen Antagonists DNA Antineoplastic Combined Chemotherapy Protocols Cytological Techniques Costs and Cost Analysis Evidence-Based Medicine diagnosis Cytokines Educational Status clinical practice patterns Squamous Cell Carcinoma Philadelphia Phase III Clinical Trials epidemiology Immunotherapy Middle Age Ploidies blood Middle Aged Urban Population surgery Communication Drug Delivery Systems Physician's Practice Patterns secondary Rural Population Prostate-Specific Antigen utilization Monte Carlo Method Oral anticancer medications Vaginal Smears Early Detection of Cancer Survival Rate Antineoplastic agents mortality Medical Oncology administration & dosage Health Resources Data Collection use Outcome Assessment (Health Care) Medical Societies Medical Education-Continuing Logistic Models Renal cell carcinoma Prostatectomy Safety Decision Making Treatment patterns Registries Biomedical Technology ethnology
Last updated on Friday, December 06, 2019